CorMedix Inc. (CRMD) Fair Value 2026

CRMD · Biotechnology ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

9.0 /10

32 fundamental signals · 9 models active

Value Trap Risk

SAFE (18/100)

Quick Summary — As of 2026-08-28, CorMedix Inc. (CRMD) trades at $8.30, versus a $10.25 median fair value across its 9 active models — 23.5% above the current price. QOC: 9.0/10. Value Trap Risk: 18/100 (SAFE). 9/13 models active. Within that set, the Bayesian DCF component alone returns $10.05.

Key Facts

Ticker
CRMD
Price
$8.30
Quality Score
9.0/10
Value Trap Risk
18/100
Models Active
9/13
Last Updated
Strength: ML-RIV suggests +119.5% upside with 61% confidence
Risk: Limited model coverage (9/13) may reduce confidence

Is CorMedix Inc. (CRMD) Undervalued or Overvalued in 2026?

According to CirclFi’s 9-model valuation engine, CorMedix Inc. (CRMD) appears undervalued as of : the median of 9 independent fair value estimates is $10.25, 23.5% above the current price of $8.30. Estimates range from $0.26 to $18.22. CRMD scores 9.0/10 on fundamental quality and 18/100 on value-trap risk.

For context, the median US equity CirclFi rates trades at an implied -23.4% versus its own 13-model consensus, across 3,809 rated companies as of 2026-08-28. CRMD’s +23.5% gap is wider than that market norm, and the Biotechnology sector median is -64.7%. Full market index →

This verdict compares price to intrinsic value only — it is not a buy or sell rating. For the decision case (bull vs bear arguments, risk factors, peers), read Should You Buy CorMedix Inc. Stock in 2026? →

What Fair Value Does Each Model Give CRMD?

9 Intrinsic Value Models vs. Current Price ($8.30)

Core Models (Unlocked)
Model Fair Value Upside
Intrinsic · High Conviction
 $10.05 +21.1%
Ensemble · Low Conviction
 $10.25 +23.5%
Scenario · High Conviction
 $14.50 +74.7%
Intrinsic · High Conviction
 $18.22 +119.5%
Unlock the Full Matrix

Access 5 additional models including EROIC Spread, Regime Cross-Sectional, and more.

$1.30 / day

Billed monthly ($39/mo) or annually ($299/yr)

Unlock All 9 Models →

Cancel anytime · No contracts · Instant access

What Is CRMD's Fair Value Range?

Spread across 9 independent models · $0.26 to $18.22

CirclFi's 9 active models place CorMedix Inc. (CRMD) between $0.26 and $18.22 per share, a spread of 175% of the median. The median of that range — $10.25 — is the fair value CirclFi publishes for CRMD, against a current price of $8.30.

Low · Regime CrossHigh · ML-RIV
$0.26median $10.25$18.22
Where the range comes from
Most bearish modelRegime Cross-Sectional$0.26
Most bullish modelML Residual Income$18.22
Model agreement7 bullish · 2 bearishwide

A band this wide is itself the finding. When independent methods land far apart, they are reading a business whose value depends heavily on which lens you apply — volatile earnings, heavy reinvestment, or an asset base that cash-flow and asset-based methods score differently. That disagreement is information: it says the choice of method matters more than usual for CRMD. Treat the median as one reading among several and compare the individual models below before acting.

Every figure above is one model's standalone output on CRMD, not a CirclFi price target. How each model works →

What Is CorMedix Inc. (CRMD) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, the weight of evidence tilts decidedly bullish for CorMedix Inc.. Trading at $8.30 against an estimated intrinsic value of $10.25, 7 of 9 active models flag meaningful upside of +23.5% at the median. The most optimistic model, ML-RIV, places fair value at $18.22 (+119.5%), while Regime Cross — the most conservative — estimates $0.26 (-96.8%). This +216.3% gap reflects genuine analytical uncertainty about CorMedix Inc.'s intrinsic worth.

What Do the Models Say About CRMD?

9 of 13 models are currently active for CRMD. Of these, 7 models suggest upside while 2 models suggest overvaluation. Taken together, their median fair value for CRMD is $10.25 — the figure CirclFi publishes as this stock's fair value. One component of that median, the Bayesian DCF, returns $10.05 on its own, implying +21.1% upside from the current price. See which stocks rank higher →

How Does CRMD Rank in Biotechnology?

Among 625 Biotechnology stocks, CRMD ranks #9 by Quality of Company score. CirclFi's QOC score of 9.0/10 evaluates 32 fundamental signals. A score of 9.0 places CRMD in the top tier.

See all Most Undervalued Biotechnology Stocks →

The Biotechnology sector introduces analytical considerations specific to biotech businesses. For CorMedix Inc., metrics like clinical trial success rate provide important context that general-purpose valuation models may underweight.

Is CRMD a Value Trap?

CirclFi's Value Trap algorithm assigns CRMD a score of 18/100 (SAFE). This indicates minimal risk. Fundamentals are healthy. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

9 of 13 models are active for CorMedix Inc.. Moderate coverage provides meaningful perspective. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi Deep Alpha Valuation Engine, CorMedix Inc. scores 9.0 out of 10 on our 32-signal quality assessment, a strong rating that demonstrates strong fundamentals across the majority of our quality signals. The QOC score synthesizes profitability margins, revenue growth reliability, debt management, and capital allocation into a single metric designed to separate durable businesses from statistically cheap ones.

The gap between the most bullish and bearish model spans +216.3% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every CRMD valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across CRMD's 9 active models, average confidence is 46%. Lower confidence may reflect limited history or high volatility.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy CorMedix Inc. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Biotechnology Stocks Should You Also Analyze?

11 related Biotechnology stocks with 13-model coverage

ONCBeOne Medicines AGQOC 9.0CGENCompugen Ltd.QOC 9.0VRTXVertex Pharmaceuticals IncorporatedQOC 9.1VCELVericel CorporationQOC 8.8HALOHalozyme Therapeutics, Inc.QOC 9.2PTCTPTC Therapeutics, Inc.QOC 8.7CELZCreative Medical Technology Holdings, Inc.QOC 5.9ABVCABVC BioPharma, Inc.QOC 5.0COCPCocrystal Pharma, Inc.QOC 4.4EXELExelixis, Inc.QOC 9.6INCYIncyte CorporationQOC 9.5

Read investment analysis: ONC · CGEN · VRTX · VCEL · HALO · PTCT · CELZ · ABVC · COCP · EXEL · INCY

Which Other Stocks Have a Similar Quality Score to CRMD?

7 companies across all industries closest to CRMD’s Quality of Company score of 9.0/10.

RLIRLI Corp.QOC 9.0DRDDRDGOLD LimitedQOC 9.0LOGILogitech International S.A.QOC 9.0XPELXPEL, Inc.QOC 9.0SKYChampion Homes, Inc.QOC 9.0FICOFair Isaac CorporationQOC 9.0NVDANVIDIA CorporationQOC 10.0

Read investment analysis: RLI · DRD · LOGI · XPEL · SKY · FICO · NVDA

Where Does CRMD Sit in CirclFi's Biotechnology Rankings?

CRMD is ranked against every other Biotechnology stock CirclFi covers in each of these screens.

See all Biotechnology stocks ranked →

What Else Do Investors Ask About CorMedix Inc.’s Valuation?

What is CorMedix Inc.'s intrinsic value in 2026?

CirclFi puts CorMedix Inc. (CRMD)'s intrinsic value at $10.25 — the median of 9 independent model estimates as of 2026-08-28, ranging from $0.26 to $18.22. One component of that median, the Bayesian DCF, runs 10,000 Monte Carlo simulations with jump-diffusion and returns $10.05 on its own. The Quality of Company score is 9.0/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is CRMD overvalued or undervalued right now?

At $8.30, 7 of 9 active models suggest CRMD may be undervalued, while 2 indicate potential overvaluation. The median of all 9 fair value estimates is $10.25, 23.5% above the current price of $8.30 — a consensus view that CRMD is undervalued. The assessment depends on which methodology best fits CorMedix Inc.'s business model in Biotechnology.

What does a Quality of Company score of 9.0 mean for CRMD?

CorMedix Inc.'s QOC of 9.0/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores above 7 indicate strong fundamentals and disciplined management.

How many valuation models does CirclFi run on CRMD?

CirclFi analyzes CRMD with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 9 of 13 are active for this stock. Read the full methodology →

Which valuation models are most bullish and most bearish on CRMD?

Of the 9 models currently active on CRMD, ML Residual Income is the most bullish at $18.22 per share, and Regime Cross-Sectional is the most bearish at $0.26. CirclFi's published fair value for CRMD is the median of that range, $10.25, not either extreme. The gap between the two ends equals 175% of the median — a wide spread, meaning the methods genuinely disagree and the median should carry less weight. Browse stocks by value-trap risk →

Is CRMD a value trap in 2026?

CorMedix Inc.'s Value Trap score is 18/100 (SAFE). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap.

Cite this analysis — “According to CirclFi’s 9-model valuation engine, CorMedix Inc. (CRMD) has a median fair value of $10.25 — 23.5% above the current price of $8.30 — as of 2026-08-28.” Source: circlfi.com/stock/CRMD/ · Methodology
Primary sources for this CRMD valuation
  • Financial statements: CorMedix Inc. 10-K and 10-Q filings on SEC EDGAR (CIK 0001410098) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for CRMD as of ; valuations recomputed .

You’ve done the research. Don’t stop at half the picture.

Stop collecting opinions. Let 9 mathematical frameworks give you clarity on CRMD.

Unlock All 9 Fair Values — $39/mo

Cancel anytime · Less than a cup of coffee · Instant access

5 models hidden for CRMD Unlock All 9 — $39/mo